ACHV vs. VNRX, TKNO, ABIO, AWH, ICCC, RGLS, CRVO, ELMD, MCRB, and CO
Should you be buying Achieve Life Sciences stock or one of its competitors? The main competitors of Achieve Life Sciences include VolitionRx (VNRX), Alpha Teknova (TKNO), ARCA biopharma (ABIO), Aspira Women's Health (AWH), ImmuCell (ICCC), Regulus Therapeutics (RGLS), CervoMed (CRVO), Electromed (ELMD), Seres Therapeutics (MCRB), and Global Cord Blood (CO). These companies are all part of the "medical" sector.
VolitionRx (NYSE:VNRX) and Achieve Life Sciences (NASDAQ:ACHV) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, community ranking, institutional ownership, dividends, risk, profitability, media sentiment and valuation.
8.1% of VolitionRx shares are held by institutional investors. Comparatively, 33.5% of Achieve Life Sciences shares are held by institutional investors. 15.4% of VolitionRx shares are held by insiders. Comparatively, 2.0% of Achieve Life Sciences shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
VolitionRx has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500. Comparatively, Achieve Life Sciences has a beta of 1.26, meaning that its stock price is 26% more volatile than the S&P 500.
Achieve Life Sciences received 326 more outperform votes than VolitionRx when rated by MarketBeat users. Likewise, 70.15% of users gave Achieve Life Sciences an outperform vote while only 27.27% of users gave VolitionRx an outperform vote.
VolitionRx presently has a consensus price target of $2.50, suggesting a potential upside of 201.57%. Achieve Life Sciences has a consensus price target of $16.33, suggesting a potential upside of 254.30%. Given VolitionRx's higher possible upside, analysts plainly believe Achieve Life Sciences is more favorable than VolitionRx.
Achieve Life Sciences has a net margin of 0.00% compared to Achieve Life Sciences' net margin of -4,557.29%. Achieve Life Sciences' return on equity of 0.00% beat VolitionRx's return on equity.
In the previous week, Achieve Life Sciences had 9 more articles in the media than VolitionRx. MarketBeat recorded 10 mentions for Achieve Life Sciences and 1 mentions for VolitionRx. VolitionRx's average media sentiment score of 0.53 beat Achieve Life Sciences' score of 0.30 indicating that Achieve Life Sciences is being referred to more favorably in the news media.
Achieve Life Sciences has lower revenue, but higher earnings than VolitionRx. Achieve Life Sciences is trading at a lower price-to-earnings ratio than VolitionRx, indicating that it is currently the more affordable of the two stocks.
Summary
Achieve Life Sciences beats VolitionRx on 10 of the 15 factors compared between the two stocks.
Get Achieve Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ACHV and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ACHV and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Achieve Life Sciences Competitors List
Related Companies and Tools
